“Empagliflozin’s Early Tubular Protective Effects in Type 2 Diabetes Patients”

https://pubmed.ncbi.nlm.nih.gov/38117325

This study found that the SGLT2 inhibitor empagliflozin can reduce urine albumin-to-creatinine ratio and estimated glomerular filtration rate in early type 2 diabetes patients with normal proteinuria, and functional magnetic resonance imaging suggests that it has early tubular protective effects.